An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
The purpose of this study is to provide continued supply of ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone to subjects from an Incyte-sponsored study of ruxolitinib that has reached its study objectives or has been terminated. This study will also provide another mechanism for reporting adverse events related to study drug safety.
Checked against the public recordLast updated Aug 17, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Incyte Corporation
- Interventions being studied
- Drug: Ruxolitinib; Drug: Capecitabine; Drug: Regorafenib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of ruxolitinib that has completed or been terminated. * Currently tolerating treatment in the parent protocol. * Currently benefiting from the treatment with ruxolitinib alone, ruxolitinib plus background cancer therapy, or background cancer therapy alone, as determined by the investigator. * Have at least stable disease, as determined by the investigator. * Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements. Exclusion Criteria: * Has been permanently discontinued from study treatment in the parent study for any reason. * Able to access ruxolitinib and/or background cancer therapy outside of the clinical study.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- UCLA Healthcare Hematology-OncologySanta Monica, California
- University of LouisvilleLouisville, Kentucky
- New York Oncology Hematology Pc.Clifton Park, New York
- Tennessee OncologyNashville, Tennessee
- University of Texas M. D. Anderson Cancer CenterHouston, Texas
- Renovatio Clinical Consultants LlcThe Woodlands, Texas
- Sp Zoz Szpital Uniwersytecki W Krakowie Oddzial Kliniczny HematologiiKrakow
- Samodzielny Publiczny Szpital KlinicznyLublin
- Instytut Hematologii I TransfuzjologiiWarsaw
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 17, 2026. Always confirm current availability with the study team.